HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sethi, G. Articles by Aggarwal, B. B. Search for Related Content PubMed PubMed Citation Articles by Sethi, G. Articles by Aggarwal, B. B.

---

MINIREVIEW

Nuclear Factor-B Activation: From Bench to Bedside

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, Texas 77030

To whom requests for reprints should be addressed at ¹ Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, TX 77030. Email: aggarwal{at}mdanderson.org

Nuclear factor-B (NF-B) is a proinflammatory transcription factor that has emerged as an important player in the development and progression of malignant cancers. NF-B targets genes that promote tumor cell proliferation, survival, metastasis, inflammation, invasion, and angiogenesis. Constitutive or aberrant activation of NF- is frequently encountered in many human tumors and is associated with a resistant phenotype and poor prognosis. The mechanism of such persistent NF-B activation is not clear but may involve defects in signaling pathways, mutations, or chromosomal rearrangements. Suppression of constitutive NF-B activation inhibits the oncogenic potential of transformed cells and thus makes NF-B an interesting new therapeutic target in cancer.

Key Words: NF-B • cancer • IKK • metastasis • invasion

This article has been cited by other articles:

				M. K. Kiessling, C. D. Klemke, M. M. Kaminski, I. E. Galani, P. H. Krammer, and K. Gulow Inhibition of Constitutively Activated Nuclear Factor-{kappa}B Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell Lymphoma Cancer Res., March 15, 2009; 69(6): 2365 - 2374. [Abstract] [Full Text] [PDF]

				K. B. Harikumar, A. B. Kunnumakkara, K. S. Ahn, P. Anand, S. Krishnan, S. Guha, and B. B. Aggarwal Modification of the cysteine residues in I{kappa}B{alpha} kinase and NF-{kappa}B (p65) by xanthohumol leads to suppression of NF-{kappa}B-regulated gene products and potentiation of apoptosis in leukemia cells Blood, February 26, 2009; 113(9): 2003 - 2013. [Abstract] [Full Text] [PDF]

				J. Y. Kim and K. Ozato The Sequestosome 1/p62 Attenuates Cytokine Gene Expression in Activated Macrophages by Inhibiting IFN Regulatory Factor 8 and TNF Receptor-Associated Factor 6/NF-{kappa}B Activity J. Immunol., February 15, 2009; 182(4): 2131 - 2140. [Abstract] [Full Text] [PDF]

				B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430. [Abstract] [Full Text] [PDF]

				B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar Targeting Cancer Stem Cells with Phytochemicals Mol. Interv., August 1, 2008; 8(4): 174 - 184. [Abstract] [Full Text] [PDF]